Intraprostatic injection of botulinum toxin type-A relieves @entity1876 in XXXX and induces prostate apoptosis in @entity235 .

@entity1 @entity235 @entity1067 @entity194 @entity1876
BACKGROUND: With the increasing interest with botulinum toxin--A (BTX-A) application in the lower urinary tract, we investigated the BTX-A effects on the @entity235 prostate and also in @entity1 with @entity1876 ( @entity1876 ) due to @entity1067 ( @entity1067 ). METHODS: Transperineal injection into the prostate using transrectal ultrasound (TRUS) was performed throughout the study. Saline with or without 100 U of BTX-A was injected into mongrel @entity235 prostate. One or 3 months later, the prostate was harvested for morphologic and apoptotic study. In addition, eight @entity1067 @entity1 refractory to alpha-blockers were treated with ultrasound guided intraprostatic injection of 200 U of BTX-A. RESULTS: In the BTX-A treated @entity235 , @entity194 and diffuse apoptosis was observed with H_E stain and TUNEL stain at 1 and 3 months. Clinically, the mean prostate volume, symptom score, and quality of life index were significantly reduced by 18.8%, 73.1%, and 61.5% respectively. Maximal flow rate significantly increased by 72.0%. CONCLUSION: Intraprostatic BTX-A injection induces prostate apotosis in @entity235 and relieves @entity1876 in @entity1 . It is therefore a promising alternative treatment for refractory @entity1876 due to @entity1067 .
